Patient case study in which CyPath Lung spared a high-risk patient with a suspicious nodule and elevated risk from an ...

According to the American Cancer Society, lung cancer is the deadliest cancer in the United States and the second most common type of cancer. A promising new approach could change that: advanced ...

LOUISVILLE, Colo., March 20, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, announced the publication of the largest lung nodule biomarker clinical ...

Researchers developed and validated a new lung cancer prediction model, Sybil-Epi, by integrating clinical and epidemiologic data with a pre-existing model.

HENDERSON, Nev., Dec. 10, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which ...

Researchers assessed the extent to which new or growing nodules detected on follow-up rounds of LDCT lung cancer screening indicated the risk for malignancy.

A U.S.-based diagnostics company is expanding its presence in lung cancer with the acquisition of assets from a firm based in the U.K. Boulder, Colorado-based Biodesix said Friday that it would buy ...

CyPath Lung, bioAffinity Technologies' noninvasive test for lung cancer, will be featured at the Cleveland Clinic's annual ...

Lung cancer remains the leading cause of cancer-related mortality globally. The detection rate of nodules has significantly increased with the implementation of health screening using low-dose spiral ...

In 2023, lung cancer was a brutal killer in Louisiana, making up about 27% of Louisiana's total cancer deaths. That amounts to more than 2,300 lives lost every year from lung cancer, according to the ...

K. Adam Lee, MD, Medical Director at the Thoracic Surgery & Lung Center of Excellence at Jupiter Medical Center, is here to share a message that affects every woman. Lung cancer is the leading cause ...